Table 1.
Absorbed doses per administered activity and TNDs for kidney, bone marrow, and salivary glands after treatment with radiolabeled PSMA ligands.
| PSMA-Ligand/ Study |
n | Range | Tumor (Gy/GBq) |
Kidney (Gy/GBq) |
Bone Marrow (Gy/GBq) |
Salivary Gland (Gy/GBq) |
|---|---|---|---|---|---|---|
| [177Lu]Lu-PSMA-617 Baum el at. [3] |
8 | mean TND |
3.3 (0.03–78) |
0.8 4.1 (0.03–97) |
0.025 132 |
1.3 2.5 |
| [177Lu]Lu-PSMA-617 Fendler et al. [9] |
15 | mean TND |
6.1 | 0.55 11 |
0.02 (0.05) 305 |
1.0 6.1 |
| [177Lu]Lu-PSMA-617 Scarpa et al. [10] |
10 | mean TND |
3.4 (1.1–7.17) | 0.6 (0.11–1.39) 4.9 (2.2–66) |
0.04 (0.02–0.1) 74 (24–290) |
1.0 (0.48–2.7) 3.8 (2.0–8.3) |
| [177Lu]Lu-PSMA-617 Violet et al [11]. |
30 | mean | 5.3 (0.41–11) | 0.39 (0.09–0.84) 14 |
0.11 (0.01–0.34) 48 |
0.58 (0.13–1.87) 9.1 |
| [225Ac]Ac-PSMA-617 Kratochwil et al. [6] |
4 | mean TND |
5.7 Sv5/MBq | 0.74 Sv5/MBq 7.7 |
0.05 Sv5/MBq 110 |
2.3 Sv5/MBq 2.5 |
| [213Bi]Bi-PSMA-617 Kratochwil et al. [7] |
3 | mean TND |
6.3 Sv5/MBq | 8.1 Sv5/MBq 0.78 |
0.52 Sv5/MBq 12 |
8.1 Sv5/MBq 1.3 |
| [212Pb]Pb-PSMA-CA012 dos Santos et al., [8] |
2 | mean TND |
140 mSv5/MBq | 49 ± 2 mSv5/MBq 2.9 |
6.2 ± 1.2 m Sv5/MBq 23 |
75 m Sv5/MBq 1.9 |
Note: The authors use of Sv, with a weight of 5, are applied in Table 1.